Skip to main content
Premium Trial:

Request an Annual Quote

Evotec, ProPharma, TNO, Mitsubishi, Keck


Evotec Folds ProPharma Subsidiary into Services Division

Evotec said last week that ProPharma Limited, Evotec's Glasgow, Scotland-based formulation subsidiary, is now conducting its business under the Evotec brand.

ProPharma will be integrated into the Evotec Services Division over the coming months, Evotec said in a statement.

Evotec has been the majority shareholder in ProPharma since it was formed as a spin-out enterprise from the University of Strathclyde in Glasgow in 2000.

Evotec said the integration will combine its experience in pharmaceutical ingredient manufacture with ProPharma's expertise in pharmaceutical formulation development, further broadening Evotec's range of drug discovery services.

TNO, Mitsubishi Pharma Enter siRNA Target Validation Pact

Dutch biotech TNO and Mitsubishi Pharma of Japan have entered into a technology development collaboration for siRNA-based target validation studies, the companies said last week.

Under the terms of the agreement, TNO will use its siRNA knockdown technology and disease models to further characterize a set of Mitsubishi's proprietary disease targets.

Financial terms of the agreement were not disclosed.

Keck Awarded $4.88M Grant to 'Rewire' Yeast

The Keck Graduate Institute of Applied Life Sciences has been awarded a 5-year, $4.88 million grant from the National Science Foundation to investigate cellular function and determine whether or not cells can be re-engineered, KGI said last week.

KGI researchers will be using the funding — made available through the NSF's Frontiers in Integrative Biological Research program — to "rewire" the molecular machinery of S. cerevisiae yeast, predict the reaction of the cellular machinery to the rewiring, and compare it with direct experiments.

KGI said it believes that if functional modules in the cell can be rewired, it may be possible to "reengineer" cells for complex functions.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.